New and developing therapies for AL amyloidosis

References

• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.
   PubMed Web of Science ®Google Scholar
• Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid. 2006;13(3):135–142.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Palladini G, Sanchorawala V, et al. Update on treatment of light chain amyloidosis. Haematologica. 2014;99(2):209–221.
   PubMed Web of Science ®Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124–5130.
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492–1495.
   PubMed Web of Science ®Google Scholar
• Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med. 2010;134(4):545–551.
   PubMed Web of Science ®Google Scholar
• Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012;119(2):488–493.
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015;125(14):2239–2244.
   PubMed Web of Science ®Google Scholar
• Gilbertson JA, Theis JD, Vrana JA, et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol. 2015;68(4):314–317.
   PubMed Web of Science ®Google Scholar
• Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–193.
   PubMed Web of Science ®Google Scholar
• Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–1579.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659–670.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Guidalotti P, Salvi F, et al. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008;51(15):1509–1510; author reply 1510.
   Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323(8):508–513.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–995.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881–1887.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427.
   PubMed Web of Science ®Google Scholar
• Berk JL, Mark EJ. Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Case 20-1998. A 53-year-old man with cardiac amyloidosis and a left pulmonary mass. N Engl J Med. 1998;338(26):1905–1913.
   PubMedGoogle Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557–561.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010;116(14):2455–2461.
   PubMed Web of Science ®Google Scholar
• Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426–3430.
   PubMed Web of Science ®Google Scholar
• Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol. 2012;87(5):465–471.
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–251.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92(10):1415–1418.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Dinner S, Witteles W, Afghahi A, et al. Lenalidomide, melphalan and dexamethasone in an immunoglobulin light chain amyloidosis patient population with high rates of advanced cardiac involvement. Haematologica. 2013;98(10):1593–1599.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012;119(23):5384–5390.
   PubMed Web of Science ®Google Scholar
• Lin G, Dispenzieri A, Kyle R, et al. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2013;24(7):793–798.
   PubMed Web of Science ®Google Scholar
• Elnegouly M, Specht K, Zoller H, et al. Liver transplantation followed by autologous stem cell transplantation for acute liver failure caused by AL amyloidosis. Case report and review of the literature. Ann Hepatol. 2016;15(4):592–597.
   PubMed Web of Science ®Google Scholar
• Grogan M, Gertz M, McCurdy A, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience. World J Transplant. 2016;6(2):380–388.
   PubMedGoogle Scholar
• Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561–3563.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19(14):3350–3356.
   PubMed Web of Science ®Google Scholar
• Milani P, Palladini G, Foli A, et al., Melphalan and dexamethasone vs bortezomib, melphalan and dexamethasone in AL amyloidosis: a matched comparison. XIVth Myeloma Workshop; 2013, Kyoto, Japan.
   Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011;46(7):970–975.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276–4282.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083–1093.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Seldin DC, Magnani B, et al. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005;36(7):597–600.
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Int Med. 2004;140(2):85–93.
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346–4352.
   PubMed Web of Science ®Google Scholar
• Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013;27(4):823–828.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Brauneis D, Shelton AC, et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial. Biol Blood Marrow Transplant. 2015;21(8):1445–1451.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–1207.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787–788.
   PubMed Web of Science ®Google Scholar
• Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008;143(3):369–373.
   PubMed Web of Science ®Google Scholar
• Wardley AM, Jayson GC, Goldsmith DJ, et al. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer. 1998;78(6):774–776.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Lust JA, et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. 1999;17(1):262–267.
   PubMed Web of Science ®Google Scholar
• Palladini G, Schonland SO, Milani P, et al. Treatment of AL amyloidosis with bendamustine. Blood. 2012;120(21):120.
   Google Scholar
• Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3(4):241–246.
   PubMedGoogle Scholar
• Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105(7):2949–2951.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Goodman HJB, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457–464.
   PubMed Web of Science ®Google Scholar
• Lane, T, Rannigan L, Foard D, et al. ALchemy – a large prospective ‘real world’ study of chemotherapy in AL amyloidosis. Blood. 2011;118(21):992.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492–496.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465–470.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol. 2012;91(1):89–92.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013;98(3):433–436.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860–4867.
   PubMed Web of Science ®Google Scholar
• Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777–4782.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397–5404.
   PubMed Web of Science ®Google Scholar
• Tapan U, Seldin DC, Finn KT, et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010;116(23):5071–5072.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92(10):1351–1358.
   PubMed Web of Science ®Google Scholar
• Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865–873.
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–4390.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4394.
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–615.
   PubMed Web of Science ®Google Scholar
• Merlini G, Sanchorawala V, Zonder JA, et al. MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): results of a Phase 1 Study. Blood. 2012;120:731.
   Google Scholar
• Terrier B, Jaccard A, Harousseau J-L, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine. 2008;87(2):99–109. DOI:10.1097/MD.0b13e31816c43b6
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Lachmann HJ, Goodman HJB, et al. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood. 2008;112(10):4009–4016.
   PubMed Web of Science ®Google Scholar
• Sachchithanantham S, Roussel M, Palladini G, et al. European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis. J Clin Oncol. 2016;34(17):2037–2045.
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol. 2011;23(2):214–220.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103(10):3960–3963.
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31(34):4319–4324.
   PubMed Web of Science ®Google Scholar
• Hwa YL, Kumar SK, Lacy MQ, et al. Impact of bone marrow plasmacytosis on outcome in patients with AL amyloidosis following autologous stem cell transplant. Blood. 2015;126:3177.
   Google Scholar
• Bochtler T, Hegenbart U, Kunz C, et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014;21(1):9–17.
   PubMed Web of Science ®Google Scholar
• Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371–1378.
   PubMed Web of Science ®Google Scholar
• Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 2014;28(12):2304–2310.
   PubMed Web of Science ®Google Scholar
• O’Nuallain B, Hrncic R, Wall JS, et al. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol. 2006;176(11):7071–7078.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Landau H, Comenzo RL, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097–1103.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148(5):760–767.
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Stefani M, Rigacci S. Beneficial properties of natural phenols: highlight on protection against pathological conditions associated with amyloid aggregation. Biofactors. 2014;40(5):482–493.
   PubMed Web of Science ®Google Scholar
• Mereles D, Buss SJ, Hardt SE, et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol. 2010;99(8):483–490.
   PubMed Web of Science ®Google Scholar
• Aus Dem Siepen F, Buss SJ, Andre F, et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol. 2015;104(8):640–647.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov: a trial for the treatment of cardiac AL-amyloidosis with the green tea compound epigallocatechin-3-gallate (TAME-AL) (TAME-AL). [cited 2016 Dec]. Available from: https://clinicaltrials.gov/ct2/show/NCT02015312?term=NCT02015312&rank=1
   Google Scholar
• Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009;113(23):5927–5937.
   PubMed Web of Science ®Google Scholar
• Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4ʹ-iodo-4ʹ-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A. 1995;92(7):2959–2963.
   PubMed Web of Science ®Google Scholar
• Gianni L, Bellotti V, Gianni AM, et al. New drug therapy of amyloidoses: resorption of AL-type deposits with 4ʹ-iodo-4ʹ-deoxydoxorubicin. Blood. 1995;86(3):855–861.
   PubMed Web of Science ®Google Scholar
• Diomede L, Rognoni P, Lavatelli F, et al. A caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 2014;123(23):3543–3552.
   PubMed Web of Science ®Google Scholar
• Wechalekar A, Whelan C, Lachmann H, et al. Oral doxycycline improves outcomes of stage III AL amyloidosis – a matched case control study. Blood. 2015;126(21):Abstract 732.
   Google Scholar